{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT01033344",
      "orgStudyIdInfo": {
        "id": "CP005"
      },
      "organization": {
        "fullName": "Circassia Limited",
        "class": "INDUSTRY"
      },
      "briefTitle": "Cat-PAD Exposure Chamber Study",
      "officialTitle": "A Double-blind, Randomized, Placebo-controlled Study to Evaluate Two Treatment Regimens of Cat-PAD in Cat Allergic Subjects Following Challenge to Cat Allergen in an Environmental Exposure Chamber"
    },
    "statusModule": {
      "statusVerifiedDate": "2010-09",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2010-01"
      },
      "primaryCompletionDateStruct": {
        "date": "2010-09",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2010-09",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2009-12-15",
      "studyFirstSubmitQcDate": "2009-12-15",
      "studyFirstPostDateStruct": {
        "date": "2009-12-16",
        "type": "ESTIMATED"
      },
      "lastUpdateSubmitDate": "2010-09-30",
      "lastUpdatePostDateStruct": {
        "date": "2010-10-01",
        "type": "ESTIMATED"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "oldNameTitle": "Dr Rod Hafner",
        "oldOrganization": "Circassia Ltd"
      },
      "leadSponsor": {
        "name": "Circassia Limited",
        "class": "INDUSTRY"
      },
      "collaborators": [
        {
          "name": "Adiga Life Sciences, Inc.",
          "class": "INDUSTRY"
        },
        {
          "name": "Cetero Research, San Antonio",
          "class": "NETWORK"
        }
      ]
    },
    "oversightModule": {
      "oversightHasDmc": false
    },
    "descriptionModule": {
      "briefSummary": "Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma. Cat-PAD is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of cat allergy.\n\nThis study will look at the efficacy, safety and tolerability of two doses of Cat-PAD in cat allergic subjects following challenge to cat allergen in an EEC.",
      "detailedDescription": "This study is designed as a randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and tolerability of Cat-PAD in cat allergic subjects with allergic rhinoconjunctivitis,subjects may also have controlled asthma. The efficacy of Cat-PAD will be explored in subjects using an(Environmental Exposure Chamber)EEC.\n\nThe study will consist of 3 study periods. In Period 1, Screening will be performed up to a maximum of 12 weeks before randomisation and may consist of one or two visits to the clinic, at the Investigator's discretion. Baseline Challenge will consist of 4 visits to the EEC at least 3 days before randomisation.\n\nIn Period 2, subjects in each cohort complying with the inclusion/exclusion criteria will be randomised to one of three groups and will receive treatment every 2 weeks (Â±2 days) for 14 weeks.\n\nIn Period 3, Post Treatment Challenge will consist of 4 visits to the EEC 18-22 weeks after the first administration in the treatment period and assessments will be performed identical to those at the baseline challenge. Follow-up will be conducted 3-10 days after PTC."
    },
    "conditionsModule": {
      "conditions": [
        "Cat Allergy"
      ],
      "keywords": [
        "Cat allergy",
        "Rhinoconjunctivitis",
        "Exposure chamber",
        "Immunotherapy",
        "Cat-PAD"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "QUADRUPLE",
          "whoMasked": [
            "PARTICIPANT",
            "CARE_PROVIDER",
            "INVESTIGATOR",
            "OUTCOMES_ASSESSOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 210,
        "type": "ESTIMATED"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Placebo",
          "type": "PLACEBO_COMPARATOR",
          "description": "Solution resembling active solution but without peptides",
          "interventionNames": [
            "Biological: Placebo"
          ]
        },
        {
          "label": "Group 1",
          "type": "EXPERIMENTAL",
          "description": "Cat-PAD dose group 1",
          "interventionNames": [
            "Biological: Cat-PAD"
          ]
        },
        {
          "label": "Group 2",
          "type": "EXPERIMENTAL",
          "description": "Cat-PAD Dose group 2",
          "interventionNames": [
            "Biological: Cat-PAD"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "Placebo",
          "description": "Intradermal injection 1x8 administrations 2 weeks apart",
          "armGroupLabels": [
            "Placebo"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "Cat-PAD",
          "description": "Intradermal injection 1x8 administrations 2 weeks apart",
          "armGroupLabels": [
            "Group 1"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "Cat-PAD",
          "description": "Intradermal injection, 1x8 administrations 2 weeks apart, alternating active and placebo",
          "armGroupLabels": [
            "Group 2"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Total Rhinoconjunctivitis Symptom Score",
          "timeFrame": "0 and 18-22 weeks after start of treatment"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Symptom scores for ocular and nasal symptoms",
          "timeFrame": "0 and 18-22 weeks after start of treatment"
        },
        {
          "measure": "Acoustic Rhinometry",
          "timeFrame": "0 and 18-22 weeks after start of treatment"
        },
        {
          "measure": "Cat Specific IgE",
          "timeFrame": "At 0 weeks and at follow up"
        },
        {
          "measure": "Adverse Events",
          "timeFrame": "During study"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female, aged 18-65 years\n* Minimum 1-year history of rhinoconjunctivitis on exposure to cats. (Subjects may also have controlled asthma)\n* Positive skin prick test to cat allergen with a wheal diameter at least 3mm larger than that produced by the negative control\n* Minimum qualifying rhinoconjunctivitis symptom scores\n\nExclusion Criteria:\n\n* \"Partly controlled\" and \"uncontrolled\" asthma\n* History of anaphylaxis to cat allergen\n* FEV1 of less than 70% of predicted\n* Subjects who cannot tolerate baseline challenge in the EEC\n* Treatment with beta-blockers,Alpha-adrenoceptor blockers, Tranquillizers or psychoactive drugs\n* A history of any significant disease or disorder (e.g. cardiovascular, pulmonary, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, neoplastic/malignant, psychiatric, major physical impairment)",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "65 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Deepen Patel, MD, CCF",
          "affiliation": "Cetero Research, San Antonio",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "Cetero Research",
          "city": "Mississauga",
          "state": "Ontario",
          "zip": "L4W 1N2",
          "country": "Canada",
          "geoPoint": {
            "lat": 43.5789,
            "lon": -79.6583
          }
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    }
  },
  "hasResults": false
}